Clinical Trials
21
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (20 trials with phase data)• Click on a phase to view related trials
Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)
- Conditions
- Long Term Follow-up
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Arbutus Biopharma Corporation
- Target Recruit Count
- 50
- Registration Number
- NCT06277037
- Locations
- 🇺🇸
Research and Education Inc., San Diego, California, United States
🇺🇸University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸Infectious Disease Care, Hillsborough, New Jersey, United States
Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Arbutus Biopharma Corporation
- Registration Number
- NCT06245291
- Locations
- 🇬🇪
Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia
🇬🇪LLC "Neolab", Tbilisi, Georgia
🇭🇰Prince Of Wales Hospital - The Chinese University Of Hong Kong, Hong Kong, Hong Kong
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB-101 Following Oral Administration in Healthy and Chronic Hepatitis B Subjects
- Conditions
- Chronic hepatitis B virus Infection
- Interventions
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Arbutus Biopharma Inc.
- Target Recruit Count
- 27
- Registration Number
- 2023-508312-39-00
- Locations
- 🇧🇬
Umbal - Prof. D-R Stoyan Kirkovich AD, Stara Zagora, Bulgaria
🇧🇬Military Medical Academy, Sofiya, Bulgaria
🇮🇹Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, Italy
Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection
- Conditions
- Chronic Hepatitis b
- Interventions
- Drug: Peg-IFNα-2a
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Arbutus Biopharma Corporation
- Target Recruit Count
- 43
- Registration Number
- NCT04980482
- Locations
- 🇺🇸
Arizona Liver Health, Tucson, Arizona, United States
🇺🇸Research and Education, Inc., San Diego, California, United States
🇺🇸University of Miami Miller School of Medicine, Miami, Florida, United States
Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection
- Conditions
- Chronic Hepatitis
- Interventions
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2022-11-21
- Lead Sponsor
- Arbutus Biopharma Corporation
- Target Recruit Count
- 110
- Registration Number
- NCT04775797
- Locations
- 🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇦🇺Nepean Hospital, Kingswood, New South Wales, Australia
🇨🇦Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
- Prev
- 1
- 2
- 3
- Next
News
Arbutus Reacquires Global Rights to Hepatitis B RNAi Therapy After Achieving Functional Cure in Eight Patients
Arbutus Biopharma has reacquired Greater China rights to imdusiran from Qilu Pharmaceutical, regaining global control of the hepatitis B RNAi therapeutic.
Imdusiran, VTP-300, and Nivolumab Combination Shows Promise in Chronic Hepatitis B
A Phase 2a trial shows that imdusiran, VTP-300, and low-dose nivolumab led to significantly greater HBsAg declines in chronic hepatitis B patients.